Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Targeted minor histocompatibility antigen typing to estimate graft-versus-host disease after allogeneic haematopoietic stem cell transplantation

Abstract

Graft-versus-host disease (GVHD) is a critical complication after allogeneic haematopoietic stem cell transplantation induced by genetic differences in donor–recipient pairs. Rigorous HLA matching has reduced GVHD, but severe GVHD still occurs. Minor histocompatibility antigens (mHAs) are another source of GVHD inducers. We designed a multi-mHA panel with 35 valid mHA loci and retrospectively analyzed 391 donor–recipient pairs with the anticipation of implementing mHA typing into clinical practice to optimize donor selection. Results showed the total mismatching in mHA loci in this panel, as well as mismatching in the GVH direction in unmatched-related recipients (UMRs) were 1.8 times and 1.3 times as those in matched-sibling recipients (MSRs) (p = 4.1e-4, p = 0.012, respectively). There was no significant association between mHA loci mismatching and grades II-IV acute GVHD (aGVHD), III-IV aGVHD, extensive chronic GVHD (cGVHD), or relapse in neither group. UMRs had an increased cumulative incidence of II-IV aGVHD (p = 0.002), but there was no statistical difference of the incidences in severe aGVHD or cGVHD (p = 0.093; p = 0.930). This is a preliminary study to explore GVHD risks brought by mHA loci mismatching in both unmatched-related recipients and matched-full-sibling recipients. Our results confirmed that stringent HLA matching is the key to reduce the risks for GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mismatching distribution.
Fig. 2: Mismatching in mHA loci in this panel seems not to affect the risks of GVHD events nor relapse.
Fig. 3: GVHD-related outcomes.

Similar content being viewed by others

References

  1. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007;109:1355–62.

    Article  CAS  Google Scholar 

  2. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003;54:29–52.

    Article  CAS  Google Scholar 

  3. Gooley AT, Chien WJ, Pergam AS, Hingorani S, Sorror LM, Boeckh Michael, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091–101.

    Article  CAS  Google Scholar 

  4. McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003–2007 versus 2013–2017 cohorts. Ann Intern Med 2020;172:229–39.

    Article  Google Scholar 

  5. Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv 2020;4:6283–90.

    Article  CAS  Google Scholar 

  6. Zeiser R, Blazar BR. Acute graft-versus-host disease-biologic process, prevention, and therapy. N Engl J Med 2017;377:216721–79.

    Google Scholar 

  7. Griffioen M, van Bergen CA, Falkenburg JH. Autosomal minor histocompatibility antigens: how genetic variants create diversity in immune targets. Front Immunol 2016;7:100.

    Article  Google Scholar 

  8. Wang W, Huang H, Halagan M, Vierra-Green C, Heuer M, Brelsford EJ, et al. Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant. Blood Adv 2018;2:2419–29.

    Article  CAS  Google Scholar 

  9. Lansford LJ, Dharmasiri U, Chai S, Hunsucker AS, Dortone SD, Keating EJ, et al. Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Adv 2018;2:2052–62.

    Article  CAS  Google Scholar 

  10. Pearson H, Daouda T, Granados DP, Durette C, Bonneil E, Courcelles M, et al. MHC class I-associated peptides derive from selective regions of the human genome. J Clin Invest 2016;126:4690–701.

    Article  Google Scholar 

  11. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD International Consortium. Biol Blood Marrow Transplant 2016;22:4–10.

    Article  Google Scholar 

  12. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215–33.

    Article  CAS  Google Scholar 

  13. Nie D, Cao P, Wang F, Zhang J, Liu M, Zhang W, et al. Analysis of overlapping heterozygous novel submicroscopic CNVs and FANCA-VPS9D1 fusion transcripts in a Fanconi anemia patient. J Hum Genet 2019;64:899–909.

    Article  CAS  Google Scholar 

  14. Chinese common and well-documented HLA alleles (CCWD) v2.2. CWD committee of China Marrow Donor Program. 2016.

  15. Martin JP, Levine MD, Storer EB, Warren HE, Zheng X, Nelson CS, et al. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood 2017;129(Feb):791–8. 9

    Article  CAS  Google Scholar 

  16. Granados DP, Sriranganadane D, Daouda T, Zieger A, Laumont CM, Caron-Lizotte O, et al. Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nat Commun 2014;5:3600.

    Article  Google Scholar 

  17. Bykova NA, Malko DB, Efimov GA. In silico analysis of the minor histocompatibility antigen landscape based on the 1000 genomes project. Front Immunol 2018;9:1819.

    Article  Google Scholar 

  18. Oostvogels R, Kneppers E, Minnema MC, Doorn RC, Franssen LE, Aarts T, et al. Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. Bone Marrow Transplant 2017;52:228–37.

    Article  CAS  Google Scholar 

  19. Akatsuka Y. TCR-Like CAR-T cells targeting MHC-bound minor histocompatibility antigens. Front Immunol 2020;11:257.

    Article  CAS  Google Scholar 

  20. Granados DP, Rodenbrock A, Laverdure JP, Cote C, Caron-Lizotte O, Carli C, et al. Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers. Leukemia 2016;30:1344–54.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge the kind support of all clinicians in the Department of Bone Marrow Transplantation.

Funding

This work was partially supported by grant from the Shandong Nature Science Fund (ZR2016HP02).

Author information

Authors and Affiliations

Authors

Contributions

DN interpreted the data, followed up with the patients, and wrote the manuscript. JZ, LL, and XL analyzed the data, graded the GVHD. JW graded the GVHD and guided the study as a clinician. JW, WZ, JC, XZ, and YT performed the sequencing of mHA typing and HLA typing, HL and WT supervised the study and revised the manuscript.

Corresponding authors

Correspondence to Hongxing Liu or Wenjun Tian.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, D., Zhang, J., Liu, L. et al. Targeted minor histocompatibility antigen typing to estimate graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 56, 3024–3028 (2021). https://doi.org/10.1038/s41409-021-01459-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01459-8

Search

Quick links